Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Where do we go from here?
View:
Post by bealert on Oct 05, 2022 10:57pm

Where do we go from here?

Any comments from anyone as to what they think will happen in the next few weeks with the price and any pending possible news?

Anyone get ANY responses from Sirona office?

I see some dumb bytch sold 5000 at .135 at the close.  Thanks for the support, whoever you are.

Or did you make the right move???

BeAlert
Comment by forhandlaren on Oct 06, 2022 2:37am
The start of the anti-aging clinical trial is clearly a major achievement that normally would get rewarded and reflected in the share price. But I'm not so sure anymore. R+F is known to be business predatores and Howard needed street cred badly after the previous failure trying to sell the compound without evidence of a clinical trial. Nevertheless, the terms were a disaster from a revenue ...more  
Comment by SironaInvestor on Oct 06, 2022 4:07am
Less pressure from the broader shareholder base. We can just hope that Antiaging testing starts soon with good results in Q1 2023. Pet deal is also promised from the CEO this year, but the same bullsh.it has been promised two years ago already. Maybe we get a bit of money in advance from Abbvie when they are the partner company for Antiaging.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities